LSLeonilda Maria Barbosa Santos

Leonilda Maria Barbosa Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leonilda Maria Barbosa Santos has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dimethyl fumarate modulates the regulatory T cell response in the mesenteric lymph nodes of mice with experimental autoimmune encephalomyelitis

    by Amanda D. R. Lima, Breno B. Ferrari, Fernando Pradella, Rodrigo M. Carvalho, Sandra L. S. Rivero, Raphael P. S. Quintiliano, Matheus A. Souza, Natália S. Brunetti, Ana M. Marques, Irene P. Santos, et al.

    Dimethyl fumarate (DMF, Tecfidera) is an oral drug utilized to treat relapsing-remitting multiple sclerosis (MS). DMF treatment reduces disease activity in MS. Gastrointestinal discomfort is a common adverse effect of the treatment with DMF. This study aimed to investigate the effect of DMF administration in the gut draining lymph nodes cells of C57BL6/J female mice with experimental autoimmune encephalomyelitis (EAE), an animal model of MS. We have demonstrated that the treatment with DMF (7.5 mg/kg) significantly reduces the severity of EAE. This reduction of the severity is accompanied by the increase of both proinflammatory and anti-inflammatory mechanisms at the beginning of the treatment. As the treatment progressed, we observed an increasing number of regulatory Foxp3 negative CD4 T cells (Tr1), and anti-inflammatory cytokines such as IL-27, as well as the reduction of PGE2 level in the mesenteric lymph nodes of mice with EAE. We provide evidence that DMF induces a gradual anti-inflammatory response in the gut draining lymph nodes, which might contribute to the reduction of both intestinal discomfort and the inflammatory response of EAE. These findings indicate that the gut is the first microenvironment of action of DMF, which may contribute to its effects of reducing disease severity in MS patients.


  • Open Access

    Defective Induction of IL-27-Mediated Immunoregulation by Myeloid DCs in Multiple Sclerosis

    by Felipe von Glehn, Nathalie Pochet, Bibek Thapa, Radhika Raheja, Maria A. Mazzola, Sushrut Jangi, Vanessa Beynon, Junning Huang, Alessandro S. Farias, Anu Paul, et al.

    The purpose of this study was to examine whether myeloid dendritic cells (mDCs) from patients with multiple sclerosis (MS) and healthy controls (HCs) become similarly tolerogenic when exposed to IL-27 as this may represent a potential mechanism of autoimmune dysregulation. Our study focused on natural mDCs that were isolated from HCs and MS patient peripheral blood mononuclear cells (PBMCs). After a 24-h treatment with IL-27 ± lipopolysaccharide (LPS), the mDCs were either harvested to identify IL-27-regulated gene expression or co-cultured with naive T-cells to measure how the treated DC affected T-cell proliferation and cytokine secretion. mDCs isolated from HCs but not untreated MS patients became functionally tolerogenic after IL-27 treatment. Although IL-27 induced both HC and untreated MS mDCs to produce similar amounts of IL-10, the tolerogenic HC mDCs expressed PD-L2, IDO1, and SOCS1, while the non-tolerogenic untreated MS mDCs expressed IDO1 and IL-6R. Cytokine and RNA analyses identified two signature blocks: the first identified genes associated with mDC tolerizing responses to IL-27, while the second was associated with the presence of MS. In contrast to mDCs from untreated MS patients, mDCs from HCs and IFNb-treated MS patients became tolerogenic in response to IL-27. The genes differentially expressed in the different donor IL-27-treated mDCs may contain targets that regulate mDC tolerogenic responses.


  • Open Access

    Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients

    by Vinícius O. Boldrini, Ana M. Marques, Raphael P. S. Quintiliano, Adriel S. Moraes, Carla R. A. V. Stella, Ana Leda F. Longhini, Irene Santos, Marília Andrade, Breno Ferrari, Alfredo Damasceno, et al.

    Background: Emerging evidence of antibody-independent functions, as well as the clinical efficacy of anti-CD20 depleting therapies, helped to reassess the contribution of B cells during multiple sclerosis (MS) pathogenesis.Objective: To investigate whether CD19+ B cells may share expression of the serine-protease granzyme-B (GzmB), resembling classical cytotoxic CD8+ T lymphocytes, in the peripheral blood from relapsing-remitting MS (RRMS) patients.Methods: In this study, 104 RRMS patients during different treatments and 58 healthy donors were included. CD8, CD19, Runx3, and GzmB expression was assessed by flow cytometry analyses.Results: RRMS patients during fingolimod (FTY) and natalizumab (NTZ) treatment showed increased percentage of circulating CD8+GzmB+ T lymphocytes when compared to healthy volunteers. An increase in circulating CD19+GzmB+ B cells was observed in RRMS patients during FTY and NTZ therapies when compared to glatiramer (GA), untreated RRMS patients, and healthy donors but not when compared to interferon-β (IFN). Moreover, regarding Runx3, the transcriptional factor classically associated with cytotoxicity in CD8+ T lymphocytes, the expression of GzmB was significantly higher in CD19+Runx3+-expressing B cells when compared to CD19+Runx3- counterparts in RRMS patients.Conclusions: CD19+ B cells may exhibit cytotoxic behavior resembling CD8+ T lymphocytes in MS patients during different treatments. In the future, monitoring “cytotoxic” subsets might become an accessible marker for investigating MS pathophysiology and even for the development of new therapeutic interventions.


  • Clinical variables that help in predicting the presence of autoantibodies in patients with acute encephalitis

    by Angélica Lizcano-Meneses, Nancy Watanabe, Felipe von Glehn, Renata Barbosa, Milena de Albuquerque, Clarissa Yassuda, Adriel S. Moraes, José Wiliam Martínez, Leonilda M.B. Santos, Fernando Cendes


  • Open Access

    Decreased Neurofilament L Chain Levels in Cerebrospinal Fluid and Tolerogenic Plasmacytoid Dendritic Cells in Natalizumab-Treated Multiple Sclerosis Patients – Brief Research Report

    by Adriel S. Moraes, Vinicius O. Boldrini, Alliny C. Dionete, Marilia D. Andrade, Ana Leda F. Longhini, Irene Santos, Amanda D. R. Lima, Veronica A. P. G. Silva, Rafael P. C. Dias Carneiro, Raphael P. S. Quintiliano, et al.

    Background: Neurofilament Light (NfL) chain levels in both cerebrospinal fluid (CSF) and serum have been correlated with the reduction of axonal damage in multiple sclerosis (MS) patients treated with Natalizumab (NTZ). However, little is known about the function of plasmacytoid cells in NTZ-treated MS patients.Objective: To evaluate CSF NfL, serum levels of soluble-HLA-G (sHLA-G), and eventual tolerogenic behavior of plasmacytoid dendritic cells (pDCs) in MS patients during NTZ treatment.Methods: CSF NfL and serum sHLA-G levels were measured using an ELISA assay, while pDCs (BDCA-2+) were accessed through flow cytometry analyses.Results: CSF levels of NfL were significantly reduced during NTZ treatment, while the serum levels of sHLA-G were increased. Moreover, NTZ treatment enhanced tolerogenic (HLA-G+, CD274+, and HLA-DR+) molecules and migratory (CCR7+) functions of pDCs in the peripheral blood.Conclusion: These findings suggest that NTZ stimulates the production of molecules with immunoregulatory function such as HLA-G and CD274 programmed death-ligand 1 (PD-L1) which may contribute to the reduction of axonal damage represented by the decrease of NfL levels in patients with MS.


  • Open Access

    Functional and microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19

    by Lucas Scardua Silva, Rafael Batista Joao, Mateus Henrique Nogueira, Italo Karmann Aventurato, Brunno Machado de Campos, Mariana Rabelo de Brito, Marina Koutsodontis Machado Alvim, Guilherme Vieira Nunes Ludwig, Cristiane Rocha, Thierry Kaue Alves Silva Souza, et al.

    Although post-acute cognitive dysfunction and neuroimaging abnormalities have been reported after hospital discharge in patients recovered from COVID-19, little is known about persistent, long-term alterations in patients who did not require hospitalization. Therefore, we conducted a cross-sectional study of 87 consecutive, non-hospitalized recovered individuals, with a median of 54 days after the laboratory confirmation of COVID-19. We performed structured interviews, neurological examination, and 3T-MRI scans. The MRI study included white matter investigation with diffusion tensor images (DTI) and seed-based resting-state functional MRI (fMRI) connectivity analyses of the default mode network (DMN). In addition, we used validated instruments to examine fatigue, symptoms of anxiety and depression, somnolence, language, memory, and cognitive flexibility. Individuals self-reported a high frequency of headaches (40%) and memory difficulties (33%). The quantitative analyses confirmed symptoms of fatigue (68% of participants), excessive somnolence (35%), symptoms of anxiety (29%), impaired cognitive flexibility (40%) and language dysfunction (33%). In addition, we observed a correlation between DTI fractional anisotropy (FA) and abnormal attention and cognitive flexibility measured by the Trail Making Test part B. The resting-state fMRI study of the DMN showed an association between higher connectivity of the posterior cingulate cortex (PCC) and higher levels of fatigue and somnolence. While greater connectivity of the PCC with bilateral angular gyri was associated with higher fatigue levels, the elevated levels of somnolence correlated with higher connectivity between the PCC and both the left thalamus and putamen.


  • Open Access

    The impact of physical functions on depressive symptoms in people with multiple sclerosis

    by Carlos Bernardo Tauil, Cintia Ramari, Flávia Martins DA Silva, Erica Brasil, Ana de David, Jaqueline Ramos Andrade Gomes, Felipe von Glehn Silva, Carlos Otávio Brandão, Leonilda Maria Barbosa DOS Santos, Leopoldo dos Santos-Neto

    Background: Multiple sclerosis (MS) is an immune-mediated disease that affects the central nervous system. The impact of MS transcends physical functions and extends to psychological impairment. Approximately 50% of people with MS develop depressive symptoms during their lifetime and depressive symptoms may predict impairment of physical functions. However, prediction of depressive symptoms based on objective measures of physical functions is still necessary. Objective: To compare physical functions between people with MS presenting depressive symptoms or not and to identify predictors of depressive symptoms using objective measures of physical functions. Methods: Cross-sectional study including 26 people with MS. Anxiety and/or depressive symptoms were assessed by the Beck Depression Inventory-II (BDI-II) and by the Hospital Anxiety and Depression Scale (HADS). Outcomes of physical functions included: the Nnnine-hole Ppeg Ttest (NHPT), knee muscle strength, balance control, the Timed Up and Go Test (TUG), and the 6-minute walk test (6MWT). Perceived exertion was measured using the Borg scale. Results: The frequency of depressive symptoms was 42% in people with MS. Balance control during a more challenging task was impaired in people with MS who presented depressive symptoms. Balance could explain 21-24% of the variance in depressive symptoms. 6MWT and TUG presented a trend of significance explaining 16% of the variance in the BDI-II score. Conclusions: Impairment in physical functions consists in a potential predictor of depressive symptoms in people with MS. Exercise interventions aiming at the improvement of physical functions, together with the treatment of depressive symptoms and conventional medical treatment, are suggested.


  • Open Access

    Depression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments

    by C.B. Tauil, A.D. Rocha-Lima, B.B. Ferrari, F.M. da Silva, L.A. Machado, C. Ramari, C.O. Brandão, L.M.B. dos Santos, L.L. dos Santos-Neto

    There is increasing evidence that neurofilament light chain (NF-L) can be considered as a biomarker for neuro-axonal damage. This polypeptide can be released into the cerebrospinal fluid (CSF) and the blood, where it can be quantified. The concentration of NF-L is elevated in patients with multiple sclerosis (MS) and psychiatric disorders. We aimed to investigate the NF-L levels in the CSF from treated MS patients and the relationship with depression or anxiety. The study involved three groups: control group (individuals without inflammation), the relapse-remitting multiple sclerosis (RRMS)-untreated group, and the RRMS-Fingo group (RRMS patients who were treated with fingolimod). MS disability was assessed by the Expanded Disability Status Scale, and depression and anxiety were evaluated by a neuropsychologist, using the Hospital Anxiety and Depression Scale, the Beck Depression Inventory-II, and the Beck Anxiety Inventory. Individual CSF samples were collected to measure NF-L levels. The results of the statistical analysis on levels of NF-L in the CSF of control subjects, RRMS-untreated patients, and RRMS-Fingo patients were significant. The relationship between depression and anxiety in RRMS-Fingo patients and NF-L levels was not statistically significant. In conclusion, MS events such as anxiety and depression appear to contribute to the onset of clinical relapses, subclinical cases, and neurodegeneration.


  • Open Access

    High proportion of Guillain-Barré syndrome associated with chikungunya in Northeast Brazil

    by Aline de Moura Brasil Matos, Fernanda Martins Maia Carvalho, Danielle Lima Malta, Cleonisio Leite Rodrigues, Alvina Clara Félix, Claudio Sergio Pannuti, Amanda Dias da Rocha Lima, Danilo Lucas Alves Espósito, Leonilda Maria Barbosa dos Santos, Felipe von Glehn, et al.


  • Open Access

    Cytotoxic Activity of CD4 T Cells During the Early Stage of Autoimmune Neuroinflammation

    by Fernando Pradella, Vinicius O. Boldrini, Ana Maria Marques, Guilherme A. D. Morais, Carolina Francelin, Rani S. Cocenza, Vitor C. Lima, Maurilio Bonora, Natalia S. Brunetti, Bruna B. Campos, et al.

    Pathogenic CD4+ T cells are capable of initiating neuroinflammation in experimental autoimmune encephalomyelitis (EAE). However, the precise effector mechanism of these autoaggressive CD4+ T cells is not entirely elucidated. Here, we demonstrated that pathogenic CD4+ T cells, upon autoantigen stimulation, developed a cytotoxic phenotype at the onset of EAE. The cytotoxic activity of pathogenic CD4+ T cells was sufficient to explain the initial myelin lesion. Consistently, CD4+ T cells of peripheral blood (PBMCs) and cerebrospinal fluid (CSF) from relapse-remitting multiple sclerosis (RRMS) patients present an enhancement of the cytotoxic profile in comparison with healthy control (HC). Moreover, cytotoxic CD4+ T cells (CD4-CTLs) are restrained in the PBMCs of Natalizumab-treated RRMS patients. Mechanistically, autoaggressive CD4-CTLs matched the majority of the molecular pathways of effector CD8+ T cells. Altogether, our findings point to potential new targets for monitoring MS diagnosis, treatment, and the development of novel therapeutic avenues.